Consulting a healthcare professional before starting peptide therapy ensures safety, especially for those with underlying health concerns
BPC 157/TB500 is not currently approved by the FDA or other regulatory agencies for medical use
Know your warning signs Establish clear personal thresholds for when to take action
(GSH) It is a linear tripeptide of L-Glutamine, L-cysteine and glycine
Dosage should be taken as directed by the physician
In rats, intraperitoneal injection of 2.5 mg CGN every 2 days for a week, followed by intraperitoneal injection of antigens (lipopolysaccharide [LPS] or sheep red blood cells [SRBC]) resulted in decreased immune response to LPS (90% inhibited) and SRBC (20% inhibited) as assessed by anti-LPS and anti-SRBC plaque forming cells in the spleen (Janezic, Mostarcia-Stojkovic, and Lukic 1979 Janezic, A., M